Candid Therapeutics, a biotech firm developing T cell engagers for autoimmune diseases, has entered a reverse merger with Nasdaq-listed Rallybio, accompanied by $505 million in private financing to support its pipeline development. The deal, announced on Monday, is set to close in mid-2026 and will see Ken Song, Candid’s current president and CEO, lead the combined company under the Candid name, with operations funded through the end of the decade.
Deal Details
The reverse merger involves Candid combining with Rallybio, after which Candid shareholders, including new investors from the financing round, will own 96.35% of the entity, while Rallybio stockholders retain 3.65%. According to Dealbreaker, the $505 million private financing will close just before the merger and includes participation from prominent investors such as Venrock Healthcare Capital Partners, RA Capital Management, Janus Henderson Investors, and others like T. Rowe Price Associates, venBio Partners, Viking Global Investors, Cormorant Asset Management, Foresite Capital, Soleus Capital, TCGX, and Vivo Capital. Post-merger, the combined company is projected to hold about $700 million in cash, enabling it to advance its lead programs, with shares expected to trade on Nasdaq under the symbol “CDRX”. This financing structure highlights a strategic influx of capital aimed at accelerating Candid’s clinical development, particularly as it prepares for Phase 2 testing of its lead candidate.
Background
Candid Therapeutics, based in San Diego, focuses on T cell engagers (TCEs), bispecific antibodies that direct T cells to eliminate disease-driving cells in autoimmune disorders. The company launched in 2024 with two TCEs licensed from Chinese biotech firms, including its most advanced program, cizutamig, which targets CD3 on T cells and BCMA on B cells and has shown favorable tolerability in Phase 1 testing with low rates of mild cytokine release syndrome. According to the source, Candid plans to advance cizutamig to Phase 2 trials for myasthenia gravis and interstitial lung disease, while other programs like CND261, targeting CD19 on B cells, are expected to yield initial clinical data in the first half of this year. In contrast, Rallybio, headquartered in New Haven, Connecticut, went public in 2021 but has faced setbacks, including discontinuing its lead program for fetal and neonatal alloimmune thrombocytopenia after Phase 2 results and shifting focus to RLYB116, a complement protein C5 inhibitor now in Phase 2 development for other conditions. This merger allows Rallybio’s assets to integrate into Candid’s broader pipeline, which also includes preclinical TCEs like CND319 and CND460.
Market Context
The biotech sector has seen increased interest in autoimmune therapies, with companies like Cullinan Therapeutics, Ouro Medicines, GSK, and Merck pursuing similar bispecific antibodies, as noted in the source material. This trend reflects a broader shift in immunotherapy from oncology to autoimmune diseases, where approaches like Candid’s “immune dimming”—aiming for partial B cell depletion—could differentiate it by offering intermittent dosing with improved safety and efficacy profiles. As a widely recognized context, the rise of such innovative treatments underscores the competitive landscape for funding in biotech, where emerging managers often seek partnerships to navigate clinical and regulatory hurdles.
What This Means for Emerging Managers
For general partners raising early funds, this deal exemplifies how strategic mergers and large private financings can provide the capital needed to transition private biotechs to public markets, potentially serving as a blueprint for securing investor backing in competitive fields. According to Dealbreaker, Candid’s approach of combining licensing deals, clinical milestones, and investor syndicates could help emerging managers demonstrate value to limited partners by highlighting paths to liquidity and pipeline advancement. Looking ahead, the merger’s closure in mid-2026, aligned with key clinical trials, may influence future fundraising strategies in biotech by showing how integrated financing can mitigate risks and accelerate development timelines.
